U.S. Epigenetics Market Size & Outlook, 2023-2030
U.S. epigenetics market, 2018-2030 (US$M)
Related Markets
U.S. epigenetics market highlights
- The U.S. epigenetics market generated a revenue of USD 5,134.9 million in 2023 and is expected to reach USD 13,100.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 14.3% from 2024 to 2030.
- In terms of segment, reagents was the largest revenue generating product in 2023.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
Epigenetics market data book summary
| Market revenue in 2023 | USD 5,134.9 million |
| Market revenue in 2030 | USD 13,100.9 million |
| Growth rate | 14.3% (CAGR from 2023 to 2030) |
| Largest segment | Reagents |
| Fastest growing segment | Services |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Reagents, Kits, Instruments, Enzymes, Services |
| Key market players worldwide | Roche Holding AG, Thermo Fisher Scientific Inc, Eisai Co Ltd, Novartis AG ADR, Element Biosciences, Dovetail Genomics, Illumina Inc, Promega, Abcam PLC |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.1% of the global epigenetics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. epigenetics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,259.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Epigenetics Market Scope
Epigenetics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. epigenetics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epigenetics market will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 32.53% in 2023. Horizon Databook has segmented the U.S. epigenetics market based on reagents, kits, instruments, enzymes, services covering the revenue growth of each sub-segment from 2018 to 2030.
The epigenetics market in the U.S. witnessed notable growth, driven by strong government support and the presence of major key players. The market is further propelled by heightened public awareness, advanced medical infrastructure, and extensive investments in research & development.
Aligned with its strategic focus on advancing RNA-based therapeutics, this initiative helped in the acquisition and expansion of Prevail Therapeutics, a leading gene therapy entity in New York City. The collaborative efforts of researchers in Boston and New York aim to harness the potential of RNA- & DNA-based technologies, offering novel therapeutic approaches for treating or preventing diseases.
Reasons to subscribe to U.S. epigenetics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. epigenetics market databook
-
Our clientele includes a mix of epigenetics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. epigenetics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. epigenetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. epigenetics market size, by product, 2018-2030 (US$M)
U.S. Epigenetics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
